Biora Therapeutics (Biora Therapeutics) EPS (Diluted) : $-8.50 (TTM As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Biora Therapeutics EPS (Diluted)?

Biora Therapeutics's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was $-0.55. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-8.50.

Biora Therapeutics's EPS (Basic) for the three months ended in Dec. 2023 was $-0.55. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $-8.50.

Biora Therapeutics's EPS without NRI for the three months ended in Dec. 2023 was $-1.02. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $-9.34.

During the past 3 years, the average EPS without NRIGrowth Rate was 54.50% per year. During the past 5 years, the average EPS without NRI Growth Rate was 28.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 6 years, Biora Therapeutics's highest 3-Year average EPS without NRI Growth Rate was 54.50% per year. The lowest was -29.20% per year. And the median was 35.30% per year.

Biora Therapeutics EPS (Diluted) Historical Data

The historical data trend for Biora Therapeutics's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biora Therapeutics EPS (Diluted) Chart

Biora Therapeutics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EPS (Diluted)

Get a 7-Day Free Trial

-163.15

-175.25

-64.33

-125.00

-7.87

Biora Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EPS (Diluted)	Get a 7-Day Free Trial															-1.64	-1.59	-1.47	-4.89	-0.55

Competitive Comparison of Biora Therapeutics's EPS (Diluted)

For the Biotechnology subindustry, Biora Therapeutics's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biora Therapeutics's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biora Therapeutics's PE Ratio distribution charts can be found below:

* The bar in red indicates where Biora Therapeutics's PE Ratio falls into.

Biora Therapeutics EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Biora Therapeutics's Diluted EPS for the fiscal year that ended in Dec. 2023 is calculated as

Diluted EPS (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-124.115	-	0)	/	15.773
	=	-7.87

Biora Therapeutics's Diluted EPS for the quarter that ended in Dec. 2023 is calculated as

Diluted EPS (Q: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-15.413	-	0)	/	27.838
	=	-0.55

EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-8.50

Biora Therapeutics (NAS:BIOR) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Biora Therapeutics EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Biora Therapeutics's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.

Biora Therapeutics (Biora Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biora Therapeutics Inc (NAS:BIOR) » Definitions » EPS (Diluted)

Comparable Companies

Traded in Other Exchanges

4ZU0:Germany 4ZU0:Germany

Address

4330 La Jolla Village Drive, Suite 300, San Diego, CA, USA, 92122

Website

https://www.bioratherapeutics.com

Biora Therapeutics Inc is a biotechnology company engaged in developing oral biotherapeutics. Its drug-device combinations could enable new treatment approaches in the delivery of therapeutics in two main areas: Targeted delivery of therapeutics to the site of disease in the gastrointestinal ("GI") tract, which is designed to improve outcomes for patients with Inflammatory Bowel Disease (IBD); and Systemic delivery of biotherapeutics, which are designed to replace injection with needle-free, oral delivery technology. Geographically, it operates only in the United States.

Executives

Athyrium Opportunities Iii Co-invest 1 Lp	10 percent owner	505 FIFTH AVENUE, FLOOR 18, NEW YORK NY 10017
Surbhi Sarna	director	ONE PENUMBRA PLACE, ALAMEDA CA 94502
Aditya P. Mohanty	director, officer: Chief Executive Officer	1010 ATLANTIC AVENUE, SUITE 102, ALAMEDA CA 94501
Jill Ann Howe	director	C/O DTX PHARMA, INC., 10655 SORRENTO VALLEY ROAD, SUITE 100, SAN DIEGO CA 92121
Athyrium Capital Management, Lp	10 percent owner	505 FIFTH AVENUE, FLOOR 18, NEW YORK NY 10017
Athyrium Opportunities Fund (a) Lp	10 percent owner	605 THIRD AVENUE, 22ND FLOOR, NEW YORK NY 10158
Hutan Hashemi	officer: Chief Compliance Officer	4330 LA JOLLA VILLAGE DRIVE, SUITE 200, SAN DIEGO CA 92122
Damon Silvestry	officer: Chief Operating Officer	4330 LA JOLLA VILLAGE DRIVE, SUITE 200, SAN DIEGO CA 92122
Jeffrey D. Alter	director	4330 LA JOLLA VILLAGE DRIVE, SUITE 200, SAN DIEGO CA 92122
Athyrium Opportunities Iii Acquisition Lp	10 percent owner	505 FIFTH AVENUE, 18TH FLOOR, NEW YORK NY 10017
Harry Stylli	director, officer: Chairman & CEO	3595 JOHN HOPKINS CT, SAN DIEGO CA 92121
Matthew T Cooper	officer: Chief Scientific Officer	4330 LA JOLLA VILLAGE DRIVE, SUITE 200, SAN DIEGO CA 92122
Athyrium Opportunities Advisers Llc	10 percent owner	1209 AVENUE OF THE AMERICAS, NEW YORK NY 10104
Athyrium Opportunities Associates Gp Llc	10 percent owner	1209 AVENUE OF THE AMERICAS, NEW YORK NY 10104
Athyrium Opportunities Associates Lp	10 percent owner	1209 AVENUE OF THE AMERICAS, NEW YORK NY 10104